GLENMARK LIFE SCIENCES
|
The Current P/E Ratio of GLENMARK LIFE SCIENCES is 30.34.
Share Price | ₹1,048.9 | Nov 22,2024 |
Market Cap | ₹12,849.0 Cr | |
Earnings-TTM | ₹423.5 Cr | TTM-Standalone Results |
Price/Earnings | 30.34x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of GLENMARK LIFE SCIENCES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹12,849.0 Cr] as on Nov 22,2024
(/) Earnings [ ₹423.5 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ 30.34x ]
Thus, for GLENMARK LIFE SCIENCES , the investors are currently willing to pay 30.34 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLENMARK LIFE SCIENCES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GLENMARK LIFE SCIENCES over the last five years.
Historical PE (Price/Earnings) ratio chart of GLENMARK LIFE SCIENCES
PE Ratio Performance Analysis for GLENMARK LIFE SCIENCES
- GLENMARK LIFE SCIENCES 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 8.78x.
- GLENMARK LIFE SCIENCES 's operated at median p/e ratio of 10.28x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK LIFE SCIENCES 's p/e ratio peaked in Mar2024 at 20.17x.
- GLENMARK LIFE SCIENCES 's p/e ratio hit its five-year low in Mar2021 of 0x.
How does GLENMARK LIFE SCIENCES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
GLENMARK LIFE SCIENCES | 423.50 | 30.34 | 12,849.0 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,136.50 | 38.73 | 431,352.0 |
CIPLA LTD | 4,485.22 | 26.76 | 120,035.0 |
DR REDDYS LABORATORIES LTD | 5,406.80 | 18.73 | 101,286.0 |
ZYDUS LIFESCIENCES LTD | 4,298.90 | 22.21 | 95,461.4 |
DIVIS LABORATORIES LTD | 1,836.00 | 86.75 | 159,265.0 |
MANKIND PHARMA LTD | 2,124.86 | 48.11 | 102,231.0 |
TORRENT PHARMACEUTICALS LTD | 1,802.00 | 59.55 | 107,306.0 |
LUPIN LTD | 2,651.94 | 35.61 | 94,430.6 |
AUROBINDO PHARMA LTD | 3,598.83 | 19.75 | 71,069.8 |
ABBOTT INDIA LTD | 1,284.66 | 45.82 | 58,859.9 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLENMARK LIFE SCIENCES 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.73x |
Max industry PE | 86.75x |
Median industry PE | 35.61x |
Average industry PE | 39.30x |
You may also like the below Video Courses